收入不平等与肺癌先进免疫治疗可及性:荷兰度伐利尤单抗的案例
该研究基于荷兰癌症登记处2017—2021年3774例接受放化疗的III期非小细胞肺癌患者数据,采用贝叶斯离散失效时间模型分析社会经济地位与距离对度伐利尤单抗可及性的影响。结果显示高SES组接受度伐利尤单抗的风险高于低SES组(HR=1.26;95%可信区间[1.06, 1.53]),距离每增加4 km则接受度伐利尤单抗减少(HR=0.93;95%可信区间[0.86, 0.99])。SES与距离交互作用的贝叶斯因子<3,证据不确定;g-formula模拟显示死亡率差异不影响SES差异。
要点
- 高SES组接受度伐利尤单抗的风险高于低SES组(HR=1.26;95%可信区间[1.06, 1.53])。
- 距离每增加4 km,接受度伐利尤单抗的风险降低(HR=0.93;95%可信区间[0.86, 0.99])。
- SES与距离交互作用的贝叶斯因子<3,证据不确定。
核心结论
- 高SES组较低SES组更常接受度伐利尤单抗(HR=1.26;95%可信区间[1.06, 1.53])。
- 距离每增加4 km导致度伐利尤单抗使用减少(HR=0.93;95%可信区间[0.86, 0.99])。
- SES与距离交互作用的贝叶斯因子<3,证据不确定。
- g-formula结果显示死亡率差异不影响SES差异。
- 次要分析显示SES在度伐利尤单抗使用上的差异多年恒定(贝叶斯因子>17)。
研究设计与样本
- 研究使用荷兰癌症登记处2017—2021年数据,纳入3774例接受放化疗的III期非小细胞肺癌患者。
- 采用贝叶斯离散失效时间模型,比较SES与距离交互作用与包含年龄、距离、SES和体能评分的基线模型。
- 拟合至死亡时间模型,并使用g-formula模拟死亡率水平均衡的情景。
主要发现
- 高SES组接受度伐利尤单抗的风险高于低SES组(HR=1.26;95%可信区间[1.06, 1.53])。
- 距离每增加4 km,接受度伐利尤单抗的风险降低(HR=0.93;95%可信区间[0.86, 0.99])。
- SES与距离交互作用的贝叶斯因子<3,证据不确定。
- g-formula结果显示死亡率差异不影响SES差异。
- 次要分析显示SES差异多年恒定(贝叶斯因子>17)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: With the introduction of immunotherapy with nonsmall cell lung cancer, prognosis of these patients has improved. However, socioeconomic differences in access to various immunotherapy treatments have been reported. In the Netherlands, such differences are not expected due to universal insurance coverage. STUDY DESIGN AND SETTING: We investigated the existence of differential susceptibility by socioeconomic status (SES) of the effect of distance to treatment hospital on access to Durvalumab in patients with stage III nonsmall cell lung cancer who received chemoradiation, and the influence of differential mortality. We used data from the Netherlands Cancer Registry (n = 3774) from the period 2017-2021. First, we fitted Bayesian discrete failure time models and compared SES-by-distance-to-hospital interaction to a baseline model including age, distance, SES, and performance score. We then fitted a time to mortality model and used both models in a g-formula to simulate a scenario where mortality levels were equalized. RESULTS: Our results showed that the high SES group received Durvalumab more often than the low SES group (hazard ratio = 1.26; 95% credible interval = [1.06, 1.53]), and even 4 km distance increase leads to less Durvalumab (hazard ratio = 0.93; 95% credible interval = [0.86, 0.99]). Bayes factor < 3 indicated inconclusive evidence for a SES by distance interaction effect, while g-formula results showed that differential mortality does not affect SES differences. Secondary analyses showed strong evidence that SES differences in using Durvalumab were constant over the years (Bayes factor > 17). CONCLUSION: Overall, these results are significant for understanding how socioeconomic inequality affects proper care and can be vital for public policy.
引用
- Katsimpokis D, Aarts MJ, Geleijnse G, et al. Income inequality and access to advanced immunotherapy for lung cancer: the case of Durvalumab in the Netherlands. J Clin Epidemiol. 2025. PMID: 39914790. doi:10.1016/j.jclinepi.2025.111711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。